Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Articles|January 1, 1999
Oncology NEWS International
- Oncology NEWS International Vol 8 No 1
- Volume 8
- Issue 1
Breast Cancer Stamp Sells Well
WASHINGTON-Postal patrons bought 45 million Breast Cancer stamps in the first 3.5 months after its release, raising about $3.6 million for research. Each stamp costs 8 cents more than a regular first-class stamp, with the additional money designated for funding breast cancer research at the National Institutes of Health and Department of Defense.
Advertisement
WASHINGTONPostal patrons bought 45 million Breast Cancer stamps in the first 3.5 months after its release, raising about $3.6 million for research. Each stamp costs 8 cents more than a regular first-class stamp, with the additional money designated for funding breast cancer research at the National Institutes of Health and Department of Defense.
The Postal Service initially printed 200 million of the stamps, and in the first few weeks after its July 29 issuance, the stamps were selling at about 1 million a day. The Postal Service anticipates a second printing early in 1999. The stamp will remain on sale at US post offices until July 2000.
Articles in this issue
almost 28 years ago
Pittsburgh to Build New Cancer Centeralmost 28 years ago
NCI Initiates Two High-Priority Tobacco Research Programsalmost 28 years ago
Hospital Strategies To Prevent Invasive Aspergillosis Spreadalmost 28 years ago
‘Cancer Patients Should Be Assertive, Know Their Rights’almost 28 years ago
EBCTCG Update of Adjuvant Treatment for Early Breast Canceralmost 28 years ago
Younger Breast Cancer Patients at Increased Risk of Recurrencealmost 28 years ago
Six Named to National Cancer Advisory Boardalmost 28 years ago
Trial Uses Vitamin A To Prevent Lung Cancer in Former Smokersalmost 28 years ago
‘Medical School Curriculum Must Include Palliative Care’almost 28 years ago
Formation of Fibrin Clots Key to AngiogenesisAdvertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?
5